Physician profile
Peter Hoang
NPI 1184889297
$2,098.37
in general payments reported to CMS, 2019-2025
12 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $54.59 · 2021: $78.68 · 2022: $177 · 2023: $121 · 2024: $204 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,033 · Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,033.08 |
| Food and Beverage | $636.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,304.12 | 2019-2025 | Clareon, Lensx, Unity |
| Abbvie INC. | $293.20 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $104.95 | 2020-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $90.30 | 2019-2021 | |
| Dompe US, INC. | $82.42 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $63.81 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $35.92 | 2024-2025 | Iyuzeh |
| Allergan, INC. | $34.99 | 2019-2021 | |
| Harrow Eye, LLC | $34.45 | 2025 | Vevye, Triesence |
| Bausch & Lomb Americas INC. | $19.20 | 2025 | Xiidra, Miebo |
| Glaukos Corporation | $18.59 | 2023 | |
| Aerie Pharmaceuticals, INC. | $16.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.